Qiagen N.V. Financial Statements
NYSE: QGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Qiagen N.V. revenue and earnings
In fiscal 2025, Qiagen N.V. generated $2.09 billion in revenue, up 5.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $424.9 million (+408.3% year over year), for a net margin of 20.3% versus a median of 19.2% in the prior 5 years. Gross margin was 62.2% (up from 48.9%) and operating margin 22.3%.
Diluted earnings per share came in at $1.94, up from $0.37. Over the last 5 fiscal years, QGEN's revenue has grown at a 2.2% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Qiagen N.V. income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.09B | 1.98B | 1.97B | 2.14B | 2.25B | 1.87B | 1.53B | 1.50B | 1.42B | 1.34B |
| Revenue growth (YoY) | +5.65% | +0.66% | -8.23% | -4.89% | +20.39% | +22.53% | +1.64% | +5.95% | +5.95% | +4.45% |
| Cost of Revenue | 790.50M | 1.01B | 731.62M | 756.96M | 800.84M | 637.63M | 521.16M | 500.89M | 494.98M | 493.34M |
| Gross Profit | 1.30B | 967.35M | 1.23B | 1.38B | 1.45B | 1.23B | 1.01B | 1.00B | 922.56M | 844.65M |
| Operating Expenses | 833.64M | 869.64M | 823.75M | 853.10M | 820.74M | 846.28M | 1.03B | 734.38M | 769.14M | 745.83M |
| Research & Development | 187.52M | 193.49M | 198.51M | 189.86M | 189.96M | 149.07M | 157.45M | 161.85M | 154.08M | 149.84M |
| Selling, General & Admin | 583.67M | 564.36M | 579.17M | 603.95M | 584.47M | 525.36M | 504.17M | 496.85M | 477.64M | — |
| Operating Income | 465.85M | 97.71M | 409.94M | 531.46M | 630.08M | 386.43M | -26.14M | 266.58M | 153.42M | 98.83M |
| Interest Expense | 33.26M | 43.84M | 53.41M | 58.36M | 54.48M | 71.32M | 74.19M | 67.29M | 49.69M | 39.02M |
| Other Income (Expense) | 24.41M | 23.44M | 19.87M | -18.86M | -4.25M | 53.04M | -51.64M | -40.84M | -39.04M | -41.92M |
| Pretax Income | 490.26M | 121.15M | 429.81M | 512.60M | 625.83M | 439.47M | -77.78M | 225.74M | 114.38M | 56.91M |
| Income Tax | 65.39M | 37.56M | 88.51M | 89.39M | 113.23M | 80.28M | -36.32M | 35.36M | 73.98M | -23.39M |
| Net Income | 424.88M | 83.59M | 341.30M | 423.21M | 512.60M | 359.19M | -41.45M | 190.38M | 40.39M | 80.40M |
| Net Income growth (YoY) | +408.28% | -75.51% | -19.35% | -17.44% | +42.71% | — | -121.77% | +371.31% | -49.76% | -38.22% |
| EPS (Basic) | 1.96 | 0.38 | 1.50 | 1.86 | 2.25 | 1.57 | -0.18 | 0.84 | 0.18 | 0.34 |
| EPS (Diluted) | 1.94 | 0.37 | 1.48 | 1.84 | 2.21 | 1.53 | -0.18 | 0.82 | 0.17 | 0.34 |
| Shares Outstanding (Basic) | 217.22M | 222.62M | 228.15M | 227.58M | 227.98M | 228.43M | 226.78M | 226.64M | 228.07M | 234.80M |
| Shares Outstanding (Diluted) | 218.88M | 224.72M | 230.62M | 230.14M | 232.03M | 234.21M | 226.78M | 233.46M | 233.01M | 238.99M |
| EBITDA | 659.60M | 300.98M | 615.27M | 739.86M | 845.01M | 591.45M | 205.32M | 473.02M | 369.87M | 311.88M |
| Gross Margin | 62.18% | 48.90% | 62.77% | 64.65% | 64.43% | 65.91% | 65.86% | 66.65% | 65.08% | 63.13% |
| Operating Margin | 22.29% | 4.94% | 20.86% | 24.82% | 27.98% | 20.66% | -1.71% | 17.75% | 10.82% | 7.39% |
| Net Margin | 20.33% | 4.23% | 17.37% | 19.76% | 22.77% | 19.20% | -2.72% | 12.68% | 2.85% | 6.01% |
This table shows 10 annual periods of Qiagen N.V.'s income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow QGEN's reporting calendar. What is a income statement?